Soligenix receives pediatric investigational plan waiver for hybryte™ in ctcl from the european medicines agency

Princeton, n.j., june 10, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received a pediatric investigation plan (pip) waiver from the european medicines agency (ema) for hybryte™ (sgx301 or hypericin), which has recently and successfully concluded a phase 3, pivotal clinical study for the treatment of early stage cutaneous t-cell lymphoma (ctcl).
SNGX Ratings Summary
SNGX Quant Ranking